SGN LIV1A

Drug Profile

SGN LIV1A

Alternative Names: SGN-LIV1A

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 24 Jul 2017 Seattle Genetics and Genentech agree to co-promote and co-develop SGN LIV1A in combination with atezolizumab in USA for Breast cancer
  • 24 Jul 2017 Seattle Genetics and Genentech plans the phase Ib/II MORPHEUS trial for Breast cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA
  • 10 Dec 2016 Interim efficacy and safety data from a phase I trial in Breast cancer released by Seattle Genetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top